[Federal Register Volume 84, Number 183 (Friday, September 20, 2019)] [Notices] [Page 49550] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2019-20413] ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA-392] Importer of Controlled Substances Application: Fisher Clinical Services, Inc. ACTION: Notice of application. ----------------------------------------------------------------------- DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before October 21, 2019. Such persons may also file a written request for a hearing on the application on or before October 21, 2019. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on July 19, 2019, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106 applied to be registered as an importer of the following basic classes of controlled substances: ------------------------------------------------------------------------ Controlled substance Drug code Schedule ------------------------------------------------------------------------ Psilocybin............................ 7437 I Methylphenidate....................... 1724 II Levorphanol........................... 9220 II Noroxymorphone........................ 9668 II Tapentadol............................ 9780 II ------------------------------------------------------------------------ The company plans to import the listed controlled substances for clinical trials only. Dated: August 20, 2019. Neil D. Doherty, Acting, Assistant Administrator. [FR Doc. 2019-20413 Filed 9-19-19; 8:45 am] BILLING CODE 4410-09-P